Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
| Revenue (TTM) | $6.51B |
| Gross Profit (TTM) | $5.07B |
| EBITDA | $2.00B |
| Operating Margin | 29.80% |
| Return on Equity | 9.18% |
| Return on Assets | 8.37% |
| Revenue/Share (TTM) | $11.22 |
| Book Value | $18.41 |
| Price-to-Book | 4.87 |
| Price-to-Sales (TTM) | 7.96 |
| EV/Revenue | 7.4 |
| EV/EBITDA | 29.17 |
| Quarterly Earnings Growth (YoY) | -25.40% |
| Quarterly Revenue Growth (YoY) | 13.60% |
| Shares Outstanding | $576.40M |
| Float | $574.50M |
| % Insiders | 0.20% |
| % Institutions | 96.02% |
Volatility is currently contracting
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
EW's TAVR and TMTT growth support its outlook, but currency pressure and intense competition remain key risks.
Edwards Lifesciences pairs accelerating structural heart growth and stronger leverage with a premium valuation that leaves less room for execution setbacks.
Edwards' 14% three-month rally reflects broad structural-heart growth, but its premium valuation raises the bar for execution.
Investors need to pay close attention to EW stock based on the movements in the options market lately.
EW beats Q2 earnings and revenue estimates as strong TAVR demand, and mitral and tricuspid therapy adoption lift results and guidance.
Edwards Lifesciences Corporation (EW) Q2 2026 Earnings Call Transcript
The medical-technology company said it now expects sales of $6.6 billion to $6.9 billion for the full year, raising the bottom end of its prior range of $6.5 billion to $6.9 billion.
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2026. Highlights Q2 sales grew 13.6% to $1.74 billion1, constant currency2 sales grew 12.5% Q2 TAVR sales grew 11.3% to $1.26 billion1; constant currency2 sales grew 10.5% Q2 TMTT sales were $195.9 million1,3, driven by portfolio of repair and replacement therapies Q2 EPS of $0.421; adjusted2 EPS of $0.781 Recent clinical data at New York Valves reinforce best-in-clas.
EW heads into Q2 earnings results with estimates calling for double-digit revenue growth as TAVR, TMTT and Surgical heart businesses remain in focus.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on EW and any ticker you trade — then tracks every position and per-strategy win rate.
